Category: Precision Medicine

What You Need to Know About Liquid Biopsies

by Janet Freeman-Daily, Founder of ROS1ders and lung cancer patient/activist, and Lecia V. Sequist, MD, MPH, The Landry Family Associate Professor of Medicine, Harvard Medical School The term “liquid biopsy” is appearing with increasing frequency in the news and lung cancer community discussions. Hundreds of presentations about liquid biopsies were offered this spring at major… Read More

Posted by ALCF Staff on August 15th, 2018

Overcoming Targeted-Therapy Resistance

The June 19 Lung Cancer Living Room featured Dr. Collin Blakely, a lung cancer specialist from UCSF, and Teri Kennedy, lung cancer survivor and patient advocate, discussing “overcoming resistance to targeted therapy.”

As Dr. Blakely stated, “The lung cancer field… Read More

Posted by ALCF Staff on June 29th, 2018

Check Out the January 2018 Edition of our newsletter

Want to know more about what we are doing at ALCF? Read our most recent newsletter to see our 2017 year in review, meet our new partner, IASLC, learn how you can get involved in our immunotherapy study, participate in a fun new way to raise funds through social sharing called the Your Cancer Game… Read More

Posted by ALCF Staff on February 1st, 2018

We Challenge You! Join ALCF and the Your Cancer Game Plan Challenge!

We’re excited to announce that we’ve joined Merck on the Your Cancer Game Plan Challenge, a social sharing program that will help us raise funds and continue our support of lung cancer patients, caregivers, healthcare providers and others. And we’d like to challenge you to join our team. During the month of February, Merck will… Read More

Posted by ALCF Staff on January 31st, 2018

Check Out the October 2017 Edition of our newsletter

Want to know more about what we are doing at ALCF? Read our most recent newsletter and learn more about Lung Cancer Awareness Month, our new #ShowUsYourMug campaign, how we are teaming up with Boehringer Ingelheim to make the holiday season a little brighter for lung cancer patients and their families, and more. Click here… Read More

Posted by ALCF Staff on November 1st, 2017

Check Out the September 2017 Edition of our newsletter

Want to know more about what we are doing at ALCF? Read our most recent newsletter and learn more about our thoughts on healthcare reform, crowdsourcing in cancer, a new study from ALCMI and Inivata, an interview with Bonnie, upcoming events, and more. Click here to read the newsletter now

Posted by ALCF Staff on October 2nd, 2017

Patient Engagement is Mandatory

Bonnie and Daryl Pritchard, PhD, from the Personalized Medicine Coalition talk about the importance of personalized medicine and how a registry that can serve as a repository for data on patients with lung cancer— is a means to empower patients and assist care providers to deliver personalized medicine in a patient-centered manner. Read the full… Read More

Posted by ALCF Staff on August 9th, 2017

Lung Cancer Updates from 2017 ASCO Annual Meeting

Each year in early June the American Society for Clinical Oncology holds its Annual Meeting (called simply “ASCO”) in Chicago. The theme for the 2017 meeting was “Making a Difference in Cancer Care WITH YOU.” Over 39,000 cancer researchers, clinicians, patient advocates, and industry representatives from around the world gathered to discuss the latest scientific… Read More

Posted by Janet Freeman-Daily on July 26th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016